Sugi Predict

Sugi Predict / Compounds / SCHEMBL18765124

SCHEMBL18765124

SCHEMBL18765124

CC(C)(C)OC(=O)N1CCCC(Cn2cc(C(=O)O)cn2)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 2/20 0.49
▸ BACE1 P56817 2/20 0.44
▸ IRAK1 P51617 1/20 0.44
▸ ACKR3 P25106 1/20 0.44
▸ CTSD P07339 1/20 0.44
▸ GLS O94925 2/20 0.43
▸ HPGDS O60760 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CHEK2 O96017 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.41
▸ GPR119 Q8TDV5 2/20 0.41
▸ ALOX5AP P20292 1/20 0.41
▸ KDM1A O60341 1/20 0.41
▸ SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18764769 0.89 L3MBTL1 (0.45) USP30GPR119
SCHEMBL673128 0.88 BACE1 (0.49) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL18764696 0.88 GPR119 (0.44) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL14009589 0.87 FEN1 (0.46) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL30736580 0.87 KDM4E (0.50) MEN1KMT2AGPR119
SCHEMBL21369624 0.86 FEN1 (0.45) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL2802074 0.86 FEN1 (0.45) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL28923952 0.84 GLS (0.45) FEN1BACE1IRAK1ACKR3CTSD
SCHEMBL672023 0.81 TGFBR1 (0.44) FEN1BACE1CTSDUSP30GPR119
SCHEMBL2795787 0.80 USP30 (0.50) FEN1BACE1IRAK1ACKR3CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
EP-3365339-B1 NOVEL FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2025-07-16 — — EP disclosed
US-20220363675-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2022-11-17 — — US disclosed
CN-114668761-A Novel ferroportin inhibitors 威佛（国际）股份公司 2022-06-28 — — CN disclosed
CN-108290878-B Novel ferroportin inhibitors 威佛（国际）股份公司 2022-04-26 — — CN disclosed
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
US-11001579-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-11 — — US disclosed
US-10364239-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2019-07-30 — — US disclosed
US-10364239-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2019-07-30 — — US disclosed
US-20180319783-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2018-11-08 — — US disclosed
US-20180297991-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2018-10-18 — — US disclosed
EP-3364967-A2 FERROPORTIN INHIBITORS Vifor (International) AG (CH) 2018-08-29 — — EP disclosed
EP-3365339-A1 NOVEL FERROPORTIN INHIBITORS Vifor (International) AG (CH) 2018-08-29 — — EP disclosed
WO-2017068090-A1 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed
WO-2017068089-A2 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed
WO-2017068089-A2 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed
WO-2017068090-A1 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139472-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 FEN1 2484/4885BACE1 2623/4885IRAK1 4589/4885
US-11066399-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 FEN1 2617/4885BACE1 2595/4885IRAK1 4755/4885
US-20180297991-A1 Novel Ferroportin Inhibitors SLC40A1, HAMP, TFRC FEN1 3684/4885BACE1 3193/4885IRAK1 4405/4885
US-11001579-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 FEN1 2617/4885BACE1 2595/4885IRAK1 4755/4885
US-10364239-B2 Ferroportin inhibitors HAMP, SLC40A1, HMOX1 FEN1 2748/4885BACE1 2459/4885IRAK1 4645/4885
US-20180319783-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, FTH1 FEN1 2998/4885BACE1 2507/4885IRAK1 4691/4885
US-20220363675-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 FEN1 2484/4885BACE1 2623/4885IRAK1 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.